Skip to main content
    L

    Larimar Therapeutics Inc (LRMR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.00
    -0.02 (-0.66%)

    Market Cap: $313.73M

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Larimar Therapeutics Inc (LRMR) Stock Forecast

    Updated Nov 17, 2026. Estimates and ratings come from consensus analyst data.

    Analysts expect Larimar Therapeutics (LRMR) to earn -$1.37 per share in the fiscal year ending Dec 31, 2026. Of 11 analysts, 11 rate the stock Buy or Strong Buy, 0 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 6 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.

    Analyst Ratings

    Scoring Strong Buy as 1 and Strong Sell as 5, the 11 ratings average 1.82, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 100% of the ratings.

    RatingAnalystsShare
    Strong Buy218.2%
    Buy981.8%
    Hold00.0%
    Sell00.0%
    Strong Sell00.0%
    Consensus
    Buy
    Total analysts
    11

    Price Target

    Analyst price targets are part of paid GNG plans. See plans

    Annual Estimates

    From the first fiscal year below to the second, the EPS consensus shows a smaller loss.

    Fiscal year ending Dec 31, 2026
    -$1.37
    EPS consensus
    Fiscal year ending Dec 31, 2027
    -$1.06
    EPS consensus, revenue $41.74M
    Next report
    Mar 17, 2027
    Estimated

    EPS range

    Fiscal year endingEPS consensusEPS rangeEPS analystsRevenue consensusRevenue rangeRev. analysts
    Dec 31, 2026-$1.37-$1.52 to -$1.148N/AN/A11
    Dec 31, 2027-$1.06-$1.49 to -$0.298$41.74M$4.63M to $164.50M11

    Quarterly Estimates

    Quarter endingEPS consensusEPS rangeEPS analysts
    Dec 31, 2026-$0.38-$0.44 to -$0.3313

    Estimate Revisions

    Across the 2 periods below, the last 30 days brought 11 upward and 0 downward EPS revisions. Raises outnumber cuts in every period.

    PeriodUp 30 daysDown 30 days
    Fiscal year ending Dec 31, 202660
    Fiscal year ending Dec 31, 202750

    EPS Trend

    Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has worsened from -$1.35.

    PeriodNow7 days ago30 days ago60 days ago90 days agoChange
    Fiscal year ending Dec 31, 2026-$1.37-$1.35-$1.35-$1.35-$1.35N/A
    Fiscal year ending Dec 31, 2027-$1.06-$1.06-$1.06-$1.06-$1.06N/A

    Frequently Asked Questions About LRMR

    What is the LRMR stock forecast?

    Consensus analyst estimates put Larimar Therapeutics's EPS at -$1.37 for the fiscal year ending Dec 31, 2026. The consensus rating from 11 analysts is Buy.

    How do analysts rate LRMR stock?

    Of 11 analysts covering Larimar Therapeutics, 2 rate it Strong Buy, 9 Buy, 0 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.

    What EPS do analysts expect from LRMR next year?

    For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is -$1.37, with estimates from -$1.52 to -$1.14 from 8 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is -$1.06, with estimates from -$1.49 to -$0.29 from 8 analysts.

    What revenue do analysts expect from Larimar Therapeutics next year?

    For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $41.74M, with estimates from $4.63M to $164.50M.

    How many analysts cover LRMR?

    11 analysts rate Larimar Therapeutics stock, and 8 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.